Stiolto respimat and Epipen drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Stiolto respimat (olodaterol hydrochloride; tiotropium bromide) and Epipen (epinephrine). Common drug interactions include laryngitis among females and cough among males.

The phase IV clinical study analyzes what interactions people have when they take Stiolto respimat and Epipen. It is created by eHealthMe based on reports of 28 people who take the same drugs from the FDA, and is updated regularly.

What is Stiolto respimat?

Stiolto respimat has active ingredients of olodaterol hydrochloride; tiotropium bromide. eHealthMe is studying from 4,438 Stiolto respimat users. Check the latest studies of Stiolto respimat.

What is Epipen?

Epipen has active ingredients of epinephrine. It is often used in anaphylaxis. eHealthMe is studying from 23,760 Epipen users. Check the latest studies of Epipen.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.



On Sep, 01, 2026

28 people who take Stiolto respimat and Epipen together, and have interactions are studied.

Stiolto respimat and Epipen drug interactions.

What are the common drug interactions of Stiolto Respimat and Epipen, by gender? *:

female:

  1. Laryngitis (inflammation of the larynx)
  2. Lung disorder (lung disease)
  3. Lymphadenopathy (disease or enlargement of lymph nodes)
  4. Nasal congestion (blockage of the nasal passages usually due to membranes lining the nose becoming swollen from inflamed blood vessels)
  5. Nasal polyps (masses that develop in the lining of the nose)
  6. Bronchitis (inflammation of the mucous membrane in the bronchial tubes)
  7. Pyrexia (fever)
  8. Urticaria (rash of round, red welts on the skin that itch intensely)
  9. Multiple allergies (allergy to multiple agents)
  10. Contusion (a type of hematoma of tissue in which capillaries)

male:

  1. Cough
  2. Nasal congestion (blockage of the nasal passages usually due to membranes lining the nose becoming swollen from inflamed blood vessels)
  3. Respiratory distress (difficulty in breathing)
  4. Abdominal pain upper
  5. Chest pain
  6. Death
  7. Fall
  8. Gastrooesophageal reflux disease (stomach contents (food or liquid) leak backwards from the stomach into the oesophagus)
  9. Infusion related reaction
  10. Sinusitis (inflammation of sinus)

What are the common drug interactions of Stiolto Respimat and Epipen, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

  1. Nasal congestion (blockage of the nasal passages usually due to membranes lining the nose becoming swollen from inflamed blood vessels)
  2. Nasal polyps (masses that develop in the lining of the nose)
  3. Nasopharyngitis (inflammation of the nasopharynx)
  4. Obstruction
  5. Oxygen saturation decreased
  6. Pain in extremity
  7. Pleurisy (inflammation of the pleurae, which causes pain when breathing)
  8. Pulmonary hypertension (increase in blood pressure in the lung artery)
  9. Rash papular (redness with papule)
  10. Respiratory tract congestion (blockage on respiratory system)

60+:

  1. Fatigue (feeling of tiredness)
  2. Chills (felling of cold)
  3. Swelling face
  4. Throat tightness
  5. Arthralgia (joint pain)
  6. Femur fracture
  7. Abdominal pain upper
  8. Aphonia (inability to produce voice)
  9. Bone pain
  10. Chest pain

What are the existing conditions these people have? *

  1. Asthma: 8 people, 28.57%
  2. Immunodeficiency Common Variable: 7 people, 25.00%
  3. High Blood Cholesterol: 2 people, 7.14%
  4. Diabetes: 2 people, 7.14%
  5. Chronic Obstructive Pulmonary Disease (a progressive disease that makes it hard to breathe): 2 people, 7.14%

* Approximation only. Some reports may have incomplete information.

Do you take Stiolto respimat and Epipen?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Stiolto respimat and Epipen:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Stiolto respimat:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Epipen:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Stiolto respimat and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Epipen and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on olodaterol hydrochloride; tiotropium bromide and epinephrine (the active ingredients of Stiolto respimat and Epipen, respectively), and Stiolto respimat and Epipen (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: